Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors

  Measured over: First 28 days of dosing (DLT evaluation period)

• Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s))

  Measured over: First 28 days of dosing (DLT evaluation period)

• Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s)

  Measured over: From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first

• Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further development

  Measured over: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first

• Phase 2: Confirm the optimal NUV-1511 target tumor types for further development

  Measured over: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first

Changes Tremor has spotted